基本信息
views: 242
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Hahn is an internationally recognized authority in the conduct of bladder cancer novel therapeutic clinical trials and translational investigations. He maintains an active clinical practice and sees patients with urothelial cancers of all locations and stages including non-muscle invasive bladder cancer. He is one of the few oncologists in the world leading a clinical trial in non-muscle invasive bladder cancer. In addition, Dr. Hahn continues to care for patients with non-urothelial genitourinary malignancies including prostate, testicular, and other rare tumors. Dr. Hahn's clinical and translational research interests focus on improving outcomes for patients with urothelial cancers through:
The identification and validation of predictive biomarkers relevant to urothelial cancers, and The identification of novel therapeutic and preventative targets for urothelial cancer patients. In addition to his efforts at Johns Hopkins, Dr. Hahn serves as the bladder cancer chairman of the Eastern Cooperative Oncology Group (ECOG), co-chairs the Hoosier Cancer Research Network genitourinary oncology clinical trials working group, participates on the NCI Bladder Cancer Task Force, and serves on the scientific advisory board of the Bladder Cancer Advocacy Network.
He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer.
The identification and validation of predictive biomarkers relevant to urothelial cancers, and The identification of novel therapeutic and preventative targets for urothelial cancer patients. In addition to his efforts at Johns Hopkins, Dr. Hahn serves as the bladder cancer chairman of the Eastern Cooperative Oncology Group (ECOG), co-chairs the Hoosier Cancer Research Network genitourinary oncology clinical trials working group, participates on the NCI Bladder Cancer Task Force, and serves on the scientific advisory board of the Bladder Cancer Advocacy Network.
He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer.
Research Interests
Papers共 253 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Roy Elias, Adam K. Aragaki, Jean H. Hoffman-Censits,Noah M. Hahn,David J. McConkey,Burles A. Johnson
Clinical Cancer Researchno. 10_Supplement (2024)
Evangelia Vlachou,Burles Avner Johnson,David McConkey,Yuezhou Jing, Andres Matoso,Noah M Hahn,Jean Hoffman-Censits
Frontiers in oncology (2024): 1377842-1377842
Jean Hoffman-Censits,Petros Grivas, Thomas Powles,Jessica Hawley, Karin Tyroller, Sonja Seeberger,Silke Guenther, Natalia Jacob,Keyvan Tadjalli Mehr,Noah M. Hahn
Burles A. Johnson III,Benjamin A. Teply, Catherine Kagemann,Bridget McGuire,Kara Lombardo,Yuezhou Jing, William Langbo, Jonathan I. Epstein,George J. Netto, Alex S. Baras,Andres Matoso,David J. McConkey,
Bladder Cancerpp.1-11, (2024)
Sunil H. Patel,Andrew T. Gabrielson, Sin Chan, Deborah Schwartz, Connie Collins,Nirmish Singla,Bruce Trock,Trinity J. Bivalacqua,Noah Hahn,Max R. Kates
Michael E Rezaee, Katherine M Mahon,Bruce J Trock,The-Hung Edward Nguyen,Armine K Smith,Noah M Hahn,Sunil H Patel,Max Kates
BMJ openno. 6 (2024): e076763-e076763
Evangelia Vlachou,Andres Matoso,David McConkey,Yuezhou Jing,Burles Avner Johnson,Noah M. Hahn,Jean Hoffman-Censits
Evangelia Vlachou,Noah M. Hahn, Alix Dabb,Burles Avner Johnson, M. Susan Lefande, Jean H. Hoffman-Censits
Journal of Clinical Oncologyno. 6_suppl (2023): 523-523
Journal of Urologyno. 6 (2023): 631-638.e1
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn